Skinvisible Completes First Sale of DermSafe Hand Sanitizer in China

Skinvisible Inc

Companies Mentioned:

Primary Exchange: OTCQB
Under the Symbol: SKVI

Skinvisible Completes First Sale of DermSafe Hand Sanitizer in China

Tuesday, June 6, 2017 9:05 AM

Germ Protection Now Available to Millions of People in China

LAS VEGAS, NV / ACCESSWIRE / June 6, 2017 / Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), developer of over 40 topical prescriptions, over-the-counter and cosmeceutical products using its patented Invisicare® polymer delivery systems, is pleased to announce it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. ("InterSpace"). InterSpace is an exporter of "made in USA" products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China.

"We were very excited to be invited to the official launch event of DermSafe in Shanghai this past week, where we shared the benefits of DermSafe to the over 1,200 enthusiastic direct sales agents in attendance," said Terry Howlett, President of Skinvisible. "This first order of 10,000 units is just the beginning for this company that is gearing up for an even larger introductory event next month. China, with a population of over 1.4 billion people, is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for our DermSafe hand sanitizer but also our OTC line of products including our anti-aging skincare line."

"We are very encouraged by the positive response to Skinvisible's DermSafe hand sanitizer with our clients," said Alexander McCoy, President of InterSpace. "There is a definite need for a product that can protect our Chinese citizens as they come in contact with various harmful germs and DermSafe delivers that protection. We anticipate further orders shortly as we continue to negotiate the sale of DermSafe and other Skinvisible formulated products in China and throughout the rest of Asia."

According to the Center for Disease Control (CDC), "China is currently experiencing its 5th epidemic of Asian H7N9 human infections. This is the largest annual epidemic to date." Recently, a number of provinces in China shut down their live poultry markets to prevent the spread of avian flu after H7N9 (avian flu virus) was detected.

Independent studies verify DermSafe provides both an immediate kill on germs, in addition to offering a 4-hour kill post application, stopping the spread of germs between people and hard surfaces. It is a non-alcohol lotion, so it does not dry the hands. The product is formulated with 4% chlorhexidine gluconate (CHG), an ingredient which has demonstrated long-term persistence in its ability to kill both gram-negative and gram-positive bacteria and viruses, including influenza viruses such as H1N1 (swine flu), H5N1, and H7N9 (avian flu), which were independently tested. DermSafe has also been successfully tested against a host of other infectious germs, including the super bug, Methicillin-Resistant Staphylococcus Aureus (MRSA), as well as Escherichia coli (E. coli), and others.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a R&D company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time along with controlling the release of actives (www.skinvisible.com).

Forward-Looking Statements:

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending March 30th, 2017).

Contact:

Doreen McMorran, Skinvisible Inc.
[email protected]
Phone: 702-433-7154

SOURCE: Skinvisible Pharmaceuticals, Inc.


SHARE ARTICLE